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SUMMARY
In human neuroblastoma, amplification of theMYCN gene predicts poor prognosis and resistance to therapy.
In a shRNA screen of genes that are highly expressed inMYCN-amplified tumors, we have identified AURKA
as a gene that is required for the growth ofMYCN-amplified neuroblastoma cells but largely dispensable for
cells lacking amplified MYCN. Aurora A has a critical function in regulating turnover of the N-Myc protein.
Degradation of N-Myc requires sequential phosphorylation by cyclin B/Cdk1 and Gsk3. N-Myc is therefore
degraded during mitosis in response to low levels of PI3-kinase activity. Aurora A interacts with both
N-Myc and the SCFFbxw7 ubiquitin ligase that ubiquitinates N-Myc and counteracts degradation of N-Myc,
thereby uncoupling N-Myc stability from growth factor-dependent signals.INTRODUCTION
Human neuroblastoma is a tumor of the peripheral sympathetic
nervous system that is derived from highly proliferative migratory
cells of the neural crest. During normal development, these neu-
roblasts undergo cell-cycle exit and differentiation when they
colonize ganglia and spinal cord areas (Grimmer and Weiss,
2006). One characteristic feature of neuroblastoma is a strongly
varying course of the disease that ranges from spontaneous
regression to progressive disease and metastasis (Westermann
and Schwab, 2002). A factor that predicts poor prognosis is
amplification of the MYCN gene, which disrupts the cell-cycle
exit and terminal differentiation that occurs during normal
neuroblast development (Grimmer and Weiss, 2006). Consistent
with this view, ectopic expression of MYCN can suppress
differentiation of neuroblastoma cells in culture.
Transgenic models have demonstrated that Myc-induced
tumors remain dependent on Myc after they have been
established, arguing that strategies that interfere with Myc func-tion may have significant therapeutic value (Arvanitis and
Felsher, 2006). Similarly, a number of experimental strategies
suggest that MYCN-amplified neuroblastoma cells are addicted
to high levels of N-Myc, at least in tissue culture (Galderisi et al.,
1999).
Neuroblastomas with amplified MYCN have a characteristic
gene expression profile (Berwanger et al., 2002). We speculated
that genes that are expressed in a MYCN-dependent manner
might be required specifically for the growth of MYCN-amplified
neuroblastomas for one of two reasons. First, tumors that
depend on high levels of N-Myc may also depend on specific
upstream regulatory factors or downstream target genes of
N-Myc that are less essential for the growth of N-Myc-indepen-
dent tumors. For example, mice carrying only a single copy of the
gene encoding ornithine decarboxylase (ODC1), a target gene
of Myc, have no detectable phenotype yet are resistant to
Myc-induced lymphomagenesis (Nilsson et al., 2005). Second,
high levels of Myc proteins induce apoptosis, and a specific
pattern of gene expression may therefore be required to suppressSIGNIFICANCE
AURKA is an oncogene that is amplified in many human tumors, and the encoded kinase Aurora A is a target for current drug
development. Here we identify Aurora A as a protein that binds to and stabilizes N-Myc. We suggest that Aurora A-mediated
stabilization of N-Myc contributes to the development of neuroblastoma since it interferes with the cell-cycle exit of neuro-
blasts in developing peripheral neurons. This function is critical for the growth ofMYCN-amplified neuroblastoma cells and
is likely to be important for other MYCN-associated tumors. Aurora A stabilizes N-Myc independently of its kinase activity.
Thus, inhibition of Aurora A activity using small molecules may fail to block a critical oncogenic function of Aurora A.Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc. 67
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Figure 1. Aurora A Is Selectively Required
for the Growth of MYCN-Amplified Neuro-
blastoma Cells
(A) shRNA-mediated depletion of N-Myc protein
and MYCN mRNA. IMR-32 and SH-EP cells were
infected with retroviruses expressing either control
scrambled shRNA or shRNA targeting MYCN, and
pools of resistant cells were selected for 48 hr. The
left panel shows immunoblots of cell lysates using
N-Myc and b-actin antibodies. The right panel
shows a qRT-PCR analysis documenting MYCN
mRNA expression relative to B2M in IMR-32 cells.
Error bars show standard deviation.
(B) Colony assays documenting the effect of
shRNAs targeting MYCN on the growth of IMR-32
and SH-EP cells. Cells were infected with the
indicated retroviruses and grown in the presence
of puromycin for 6 days. At that time, plates were
fixed and stained.
(C) Summary of colony assays analyzing the effect
of MYCN depletion in eight neuroblastoma cell
lines. Assays were performed as in (B).
(D) N-Myc induces expression of Aurora A. SH-EP
cells were infected with retroviruses expressing an
N-Myc-ER chimeric protein. 4-hydroxytamoxifen
(4-OHT) was added, and lysates were prepared
24 hr later and probed with the indicated anti-
bodies. Cdk2 was used as a loading control in
most experiments.
(E) Colony assays documenting the effect of two
different shRNAs targeting AURKA in the same
eight neuroblastoma cell lines shown in (C). The
experiment was carried out as described in (B).
(F) Immunoblots documenting the effect of
shRNAs targeting AURKA on Aurora A protein
levels. The indicated cells were infected with retro-
viruses expressing control shRNA or either of two
AURKA shRNAs. Pools of resistant cells were
analyzed by immunoblotting 5 days after infection.
Note that the Aurora A blots of the amplified cell
lines were exposed 4-fold shorter to account for
the higher expression of AURKA.apoptosis (Valsesia-Wittmann et al., 2004). In this manner,
MYCN-amplified neuroblastomas might depend not only on
N-Myc itself but also on individual genes that are contained in
their expression profile. If so, inhibition of such genes might
uncover ‘‘synthetic lethal’’ effects that allow selective interference
with the growth of MYCN-amplified neuroblastomas (Kaelin,
2005). To identify possible synthetic lethal interactions, we per-
formed a shRNA screen analyzing 194 genes that are expressed
in a manner dependent on amplified MYCN in human neuroblas-
toma or that are known to be direct target genes of Myc.
RESULTS
To determine whether MYCN-amplified neuroblastoma cells
depend on N-Myc, we designed retroviral shRNA vectors68 Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc.targeting MYCN and tested them initially in IMR-32 cells, which
have amplified MYCN, and SH-EP cells, which have a single-
copy, silenced MYCN gene (Figure 1A). Both cell lines were
stably transfected with plasmids expressing the ecotropic retro-
viral receptor and a hygromycin resistance gene, and pools of
resistant cells were used in the subsequent experiments. shRNA
vectors targetingMYCN led to a reduction inMYCNmRNA and in
N-Myc protein levels in IMR-32 cells, whereas no N-Myc protein
was detectable in SH-EP cells (Figure 1A). Knockdown ofMYCN
led to a strong reduction in colony formation of IMR-32 cells, but
not of SH-EP cells (Figure 1B). Fluorescence-activated cell sort-
ing (FACS) analysis showed that depletion of MYCN delayed
progression of IMR-32 cells through the cell cycle but did not
induce apoptosis (see Figure S1 available online). shRNAs
targeting MYCN inhibited proliferation of three out of four
Cancer Cell
Aurora A Stabilizes N-MycMYCN-amplified cells tested, the exception being
SK-N-BE(2)C cells (Figure 1C). In contrast, none of four neuro-
blastoma lines lacking amplifiedMYCN depended on expression
of N-Myc. In addition, a pool of three additional vectors express-
ing shRNAs targeting MYCN reduced the rate of proliferation of
IMR-32 relative to SH-EP cells (Table S1). In contrast, control
scrambled shRNA vectors did not affect the relative rate of prolif-
eration of IMR-32 versus SH-EP cells. This demonstrates that the
majority of MYCN-amplified cell lines, but not neuroblastoma
cells lacking amplifiedMYCN, depend on N-Myc for proliferation.
In order to identify additional genes selectively required for the
growth of MYCN-amplified neuroblastoma cells, we selected
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Figure 2. Aurora A Is Required for Cell-Cycle Progression ofMYCN-
Amplified Neuroblastoma Cells
(A) Growth curve of IMR-32 cells infected with two control shRNAs (scram-
bled-sh and GFP-sh) or two shRNAs targeting AURKA. IMR-32 cells were
infected with the indicated retroviruses and selected. Counting was begun
3 days after infection (day 1 in graph). For each day and each shRNA, three
plates were counted and averaged. Error bars show standard deviation of
triplicate samples.
(B) Summary of FACS analysis documenting the effects of Aurora A depletion
on cell cycle in IMR-32 cells. Cells were infected as before, and resistant cell
pools were harvested during exponential growth in 10% FBS. For each
condition, the cell-cycle distribution of triplicate samples after staining with
propidium iodide was measured at days 1, 2, and 3, and all nine samples
were averaged. Error bars show standard deviation. No significant number
of sub-G1 cells was detected in any condition.
(C) Effect of Aurora A depletion on length of cell-cycle phases. The data ob-
tained in (A) and those obtained from the FACS analysis in (B) were combined
to calculate the length of each phase of the cell cycle of IMR-32 cells. Error bars
show standard deviation calculated via the Gaussian error propagation law.194 genes on the basis of two criteria: First, we selected all
67 genes that we had previously found to be expressed at an
enhanced level in MYCN-amplified primary neuroblastomas
(Berwanger et al., 2002). Second, we used a public database
(www.myc-cancer-gene.org) to extract all genes known to be
direct targets of Myc (for which binding of Myc to the promoter
had been demonstrated) and that are induced by Myc. At the
time we started these experiments, these were additional 127
genes (Table S1). For each gene, three retroviral shRNA vectors
were either picked from a preexisting library (Berns et al., 2004)
(61 genes) or cloned from oligonucleotides (133 genes) and
pooled before transfection of Phoenix-Eco packaging cells.
Control experiments using ten randomly picked shRNA pools
showed that both cell lines displayed similar knockdown effi-
ciencies for each pool. Specifically, 60% of the shRNA pools
used resulted in a significant (2-fold or more) knockdown of their
target gene in both cell lines (data not shown).
Subsequently, we infected both IMR-32 and SH-EP cells with
each of the 194 pools of shRNA vectors, selected resistant cells,
and estimated a proliferation rate of cell pools from plates
stained at a fixed time point after infection. Using a reduction
in growth rate similar to or better than the MYCN shRNA pool
as cutoff, the experiment identified a group of 17 genes that,
when inhibited with shRNA, reproducibly inhibited the growth
of IMR-32 cells but had no or little effect on SH-EP cells (Table
S1). We focused on Aurora A in the subsequent analysis since
the gene encoding Aurora A (AURKA) is amplified in a subset
of human neuroblastomas, providing genetic evidence for
a selective pressure for enhanced Aurora A levels in this tumor
(Zhou et al., 1998). Previous microarray analyses have demon-
strated elevated levels of AURKA mRNA in MYCN-amplified
relative to nonamplified primary neuroblastomas, suggesting
that high levels of N-Myc directly or indirectly enhance expres-
sion of AURKA mRNA (e.g., Berwanger et al., 2002). We
confirmed these findings by analyzing Aurora A protein and
AURKA mRNA expression in multiple primary neuroblastomas
(Figure S2). Furthermore, activation of a conditional allele of
MYCN (MYCN-ER) (Schulte et al., 2008) in SH-EP cells induced
expression of Aurora A protein and AURKA mRNA even in expo-
nentially proliferating cells (Figure 1D and data not shown).
We tested two different shRNAs targetingAURKA (AURKA-sh)
in the same eight neuroblastoma cell lines that had been
tested for dependence on N-Myc. We found that expression of
AURKA-sh inhibited proliferation of the same three MYCN-
amplified neuroblastoma cell lines that depend on high N-Myc
protein levels for proliferation, but none of the cell lines that do
not depend on N-Myc (Figure 1E). Both shRNAs led to a 3- to
4-fold reduction in AURKA mRNA and Aurora A protein levels
in most of the cell lines, with minor variations (Figure 1F and
data not shown). Therefore, the differential effect on cell prolifer-
ation is not due to different knockdown efficiencies. Five addi-
tional AURKA-sh vectors that led to only a small or no reduction
inAURKAmRNA levels had no effect on the proliferation of either
IMR-32 or SH-EP cells, demonstrating a close correlation
between knockdown efficiency and biological effect (data not
shown).
Growth curves showed that expression ofAURKA-sh inhibited
the exponential growth of IMR-32 cells (Figure 2A), but not of
SH-EP cells (data not shown). FACS analysis revealed thatCancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc. 69
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Aurora A Stabilizes N-Mycdepletion of Aurora A did not induce apoptosis but led to an
increase in the percentage of cells in the G1 phase of the cell
cycle and a concomitant decrease in the number of cells in
S phase (Figure 2B). We used the growth curves to estimate
doubling times and combined both pieces of information to
calculate the length of each phase of the cell cycle (Figure 2C).
We concluded that depletion of Aurora A led to an increase in
length of all phases of the cell cycle of IMR-32 cells, with the
effect being strongest for the G1 phase. Therefore, the effect
of Aurora A depletion in MYCN-amplified cells is not restricted
to the G2/M phase, when the kinase activity of Aurora A is high-
est (Hirota et al., 2003).
In order to identify potential effectors that might cause this
phenotype, we performed a microarray analysis of IMR-32 cells
expressing either control scrambled shRNA or shRNAs targeting
AURKA. The analysis showed that depletion of Aurora A affected
expression of many genes. Gene set enrichment analysis (GSEA)
A B
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Figure 3. Molecular Analysis of Aurora A Depletion in
MYCN-Amplified Neuroblastoma Cells
(A) qRT-PCR analysis documenting selective upregulation of
two p53 target genes (P21CIP1 and PLK2), three glycolytic
genes (ENO2, PKM2, and ALDOC), and the cell-cycle gene
MAD2L1 in IMR-32 cells, but not in SH-EP cells. Note that
MAD2L1 is a direct target gene of N-Myc (Berwanger et al.,
2002). Error bars indicate standard deviation.
(B) Immunoblots documenting protein levels of N-Myc, p53,
p21Cip1, and Aurora A in pools of IMR-32 cells infected with
retroviruses expressing either control shRNA or two different
shRNAs targeting AURKA.
(C) A dominant-negative allele of p53 (p53DD) abrogates
induction of p21Cip1 in response to Aurora A depletion.
IMR-32 cells were infected with either empty vector (control)
retroviruses or retroviruses expressing p53DD. Resistant
clones were superinfected with retroviruses expressing either
control shRNA or two different shRNAs targeting AURKA. The
panels show immunoblots using the indicated antibodies in
pools of resistant cells.
(D) Expression of p53DD does not relieve inhibition of prolifer-
ation by depletion of Aurora A. The upper two panels show
growth curves of IMR-32 cells infected with the indicated
retroviruses. Error bars indicate standard deviation. The lower
panel shows doubling times calculated from these curves
(averaged for control shRNA and shRNAs targeting AURKA).
(E) Colony assays documenting the effect of depletion of
Aurora A on IMR-32 cells and on IMR-32 cells superinfected
with retroviruses expressing MYCN.
(F) Immunoblots documenting expression of Aurora A, N-Myc,
and N-Myc phosphorylated at T58 in IMR-32 cells infected
with the indicated viruses. Numbers at bottom indicate the
ratio of N-Myc expression (averaged from the N-Myc and
the N-Myc-pT58 blots) to expression of Cdk2.
(Subramanian et al., 2005) and Ingenuity Pathways
Analysis (www.ingenuity.com) revealed a close
similarity between the genes induced upon deple-
tion of Aurora A and genes induced by genotoxic
stress. Examples are the cell-cycle inhibitor
p21Cip1 (P21CIP1) and polo-like kinase 2 (PLK2)
(Figure 3A; Figure S3A). Furthermore, the analysis
showed that the set of genes downregulated
upon depletion of Aurora A was enriched in genes
encoding glycolytic enzymes (shown for enolase 2 [ENO2], pyru-
vate kinase M2 [PKM2], and aldolase [ALDOC] in Figure 3A)
and in cell-cycle proteins (shown for MAD2L1), functions
that have been associated with target genes of Myc. Compar-
ison with the database of Myc target genes confirmed that
depletion of Aurora A reduced expression of many such genes
(Figure S3B). qRT-PCR analysis showed that both responses
were more prominent in IMR-32 cells since depletion of Aurora
A had little effect on expression of these genes in SH-EP cells
(Figure 3A).
Upregulation of P21CIP1 in response to genotoxic stress is
mediated by p53, suggesting that depletion of Aurora A might
activate the function of p53. Indeed, Aurora A phosphorylates
p53 and promotes its nuclear export and degradation (Katayama
et al., 2004). Therefore, high levels of Aurora A might be required
to restrict the function of p53 in the presence of elevated levels of
N-Myc. Consistent with this view, immunoblots showed that
70 Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc.
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Aurora A Stabilizes N-Mycdepletion of Aurora A elevated both p21Cip1 and p53 protein
levels (Figure 3B). Cells depleted of Aurora A also showed
a decrease in levels of N-Myc protein, which could account for
the reduced expression of Myc target genes (Figure 3B). Further-
more, N-Myc repressed expression of p21Cip1 (Figure S4A). As
a consequence, a reduction in N-Myc levels may contribute to
upregulation of P21CIP1 mRNA levels.
To test whether induction of p53 mediates the effect of
AURKA-sh on the proliferation of IMR-32 cells, we expressed a
carboxy-terminal fragment of p53, p53DD, which acts in a domi-
nant-negative manner (Gottlieb et al., 1994). We then super-
infected these cells with retroviruses expressing AURKA-sh
(Figure 3C). Expression of p53DD abrogated induction of
p21Cip1 and led to constitutively elevated expression of endog-
enous p53, indicative of repression of MDM2. p53DD caused
a moderate reduction in the growth rate of IMR-32 cells but did
not relieve the inhibition of proliferation caused by depletion of
Aurora A (Figure 3D). FACS analysis showed that the arrest in
response to Aurora A depletion was shifted toward the G2/M
phase in IMR-32/p53DD cells, consistent with the reduced
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Figure 4. Aurora A Regulates N-Myc Protein Stability
(A) Immunoblots documenting steady-state levels of N-Myc
and Aurora A protein (left panel) and qRT-PCR analysis
documenting levels of AURKA andMYCNmRNAs (right panel)
in IMR-32 cells infected with either control shRNA or AURKA-
sh-2. Error bars show standard deviation.
(B) Immunoblots documenting the stability of N-Myc in IMR-32
cells expressing either control shRNA or shRNA targeting
AURKA. At the start of the experiment, cells were treated
with cycloheximide (CHX). Lysates were prepared at the
indicated times after addition of CHX and probed with the indi-
cated antibodies.
(C) Stabilization of N-Myc by expression of Aurora A. SH-EP
cells were cotransfected with CMV-driven vectors expressing
MYCN and AURKA as indicated. The leftmost two lanes docu-
ment steady-state levels of N-Myc and Aurora A 48 hr after
transfection. qRT-PCR analysis showed that Aurora A did
not affect the MYCN mRNA levels in this experiment (data
not shown). Subsequently, CHX was added to cells, and
lysates were prepared at the indicated times after addition of
CHX and analyzed by immunoblotting. Note that the exposure
time of the upper middle panel documenting stability of N-Myc
in the absence of Aurora A is 4-fold longer than the other
panels to equalize the signal at the 0 hr time point.
(D) Quantification of stability assays. The left panel shows
a quantification of the results shown in (B); the right panel
shows a quantification of the results shown in (C). Levels of
N-Myc are normalized to Cdk2.
p21Cip1 expression (Figure S4B). In contrast,
moderate elevation of N-Myc levels using recombi-
nant retroviruses alleviated the suppression of
colony formation by AURKA-sh (Figures 3E and
3F), indicating that the reduction in N-Myc levels
is the critical mechanism by which depletion of
Aurora A inhibits proliferation. In support of this
notion, expression of AURKA-sh caused a reduc-
tion in N-Myc expression in three additional
MYCN-amplified cell lines tested (Figure S5A). In
contrast, effects on p53 were not consistent
between these four cell lines (data not shown). Finally, depletion
of Aurora A had no effect on steady-state levels of c-Myc (data
not shown), providing an explanation for the observed specificity
of dependence on Aurora A.
Depletion of Aurora A in IMR-32 cells reduced the steady-state
levels of N-Myc protein but led to a slight increase in MYCN
mRNA levels (Figure 4A), arguing that Aurora A regulates
N-Myc levels via a posttranscriptional mechanism. Indeed,
depletion of Aurora A led to an increased turnover of N-Myc
protein, which became apparent when IMR-32 cells were treated
with cycloheximide to block new protein synthesis and cells were
harvested at different time points afterwards (Figure 4B); under
these conditions, depletion of Aurora A reduced the half-life of
endogenous N-Myc from 99 to 55 min (Figure 4D). Conversely,
coexpression of Aurora A strongly enhanced steady-state levels
of N-Myc upon transient transfection of CMV-driven expression
vectors in SH-EP cells, and this corresponded to an increase in
N-Myc stability (Figures 4C and 4D); pulse-chase experiments
using 35S labeling confirmed this result (Figure S5B). We
concluded that Aurora A stabilizes the N-Myc protein.Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc. 71
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Figure 5. Aurora A Stabilizes N-Myc by Counteracting Fbxw7-
Mediated Degradation
(A) Depletion of FBXW7 enhances steady-state levels of N-Myc. IMR-32 cells
were infected with control shRNA vectors or with shRNA targeting FBXW7.
After selection, cells were harvested and immunoblots were probed with anti-
bodies against Fbxw7 and N-Myc (left panel). In parallel, FBXW7 mRNA levels
were determined relative to RPS14 (right panel). Error bars show standard
deviation.
(B) Aurora A inhibits Fbxw7-mediated degradation of N-Myc. SH-EP cells were
transfected with CMV-driven expression vectors encoding N-Myc, Aurora A,
and FLAG-tagged Fbxw7a or Fbxw7g as indicated. Forty-eight hours after
transfection, cells were lysed and immunoblots were probed with N-Myc or
FLAG antibodies. The numbers refer to the amount (in mg) of plasmid that
was transfected.
(C) Fbxw7a binds to wild-type N-Myc via T58 and S62. SH-EP cells were
transfected with CMV-driven expression vectors encoding either wild-type
N-Myc (MYCN-WT) or N-Myc(T58A;S62A) (MYCN-mut) and FLAG-tagged
Fbxw7a as indicated. Forty-eight hours after transfection, cells were lysed
and lysates were immunoprecipitated with N-Myc, FLAG, or control antibodies.
Input lanes correspond to 5% of the material used for immunoprecipitations. To
block proteasomal degradation, the proteasome inhibitor MG-132 was added
to the cells 4 hr before harvesting. Asterisk denotes the IgG heavy chain.72 Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc.In neuronal progenitor cells, degradation of N-Myc requires
phosphorylation of threonine 58 (T58) by Gsk3 (Sjostrom et al.,
2005). The surrounding sequence (Mycbox I) is identical to that
in c-Myc, and the corresponding residue in c-Myc is recognized
by the SCFFbxw7 ubiquitin ligase, suggesting that degradation of
N-Myc is carried out by the same complex (Yada et al., 2004).
Consistent with this view, depletion of Fbxw7 led to an accumu-
lation of N-Myc in IMR-32 cells (Figure 5A). Conversely, expres-
sion of either the nuclear or the nucleolar isoform of Fbxw7
(Fbxw7a or Fbxw7g; Welcker et al., 2004) led to a strong
decrease in N-Myc protein levels upon cotransfection in
SH-EP cells (Figure 5B). Coexpression of increasing amounts
of AURKA abolished the Fbxw7-mediated decrease in N-Myc
levels. In both N-Myc and c-Myc, phosphorylation of T58 by
Gsk3 requires a priming phosphorylation at serine 62 (S62);
mutation of both residues in c-Myc abolishes the interaction
with SCFFbxw7 (Yada et al., 2004). To test whether stabilization
of N-Myc by Aurora A is mediated by inhibition of SCFFbxw7,
we generated a mutant allele of N-Myc in which both T58 and
S62 are replaced by alanine (MYCN-mut). Mutation of both resi-
dues strongly attenuated the interaction of N-Myc with Fbxw7
(Figure 5C). Consistently, expression of Fbxw7a strongly
reduced steady-state levels of wild-type N-Myc, and this was
reversed by coexpression of Aurora A; in contrast, neither
Fbxw7a nor Aurora A had a significant effect on levels of the
mutant N-Myc protein (Figure 5D). We concluded that stabiliza-
tion of N-Myc by Aurora A occurs via inhibition of SCFFbxw7-
mediated degradation.
We considered several models of how Aurora A might affect
degradation of N-Myc by SCFFbxw7. To test whether phosphory-
lation of either Fbxw7 or N-Myc is required for this effect, we
generated a total of eight different mutant alleles of AURKA, all
of which have previously been reported to be deficient in kinase
activity. With a single exception (AURKA-S342D, which was
expressed at lower levels than the other alleles), each mutant
was as capable as wild-type Aurora A in stabilizing N-Myc
upon transient transfection into SH-EP cells (Figure 5E; Fig-
ure S6A). We confirmed that one of these alleles, D274N, is
unable to phosphorylate recombinant histone H3 in vitro (Fig-
ure 5E). Furthermore, treatment of transfected cells with hesper-
adin, an inhibitor of Aurora kinases, abolished phosphorylation of
histone H3 but had no effect on stabilization of N-Myc by Aurora
A (Figure S6B) (Hauf et al., 2003). Finally, treatment of IMR-32
cells with hesperadin had no effect on endogenous N-Myc levels
(D) The effects of both Fbxw7 and Aurora A are specific for wild-type N-Myc.
SH-EP cells were transfected with vectors encoding FLAG-tagged Fbxw7a,
Aurora A, and either wild-type N-Myc or N-Myc(T58A;S62A); + and ++ reflect
the amount of transfected plasmid. Forty-eight hours after transfection, cells
were lysed and immunoblots were probed with the indicated antibodies.
(E) Stabilization of N-Myc by Aurora A is independent of kinase activity. SH-EP
cells were transfected with CMV-driven expression vectors encoding either
wild-type Aurora A or Aurora A(D274N). Forty-eight hours after transfection,
cells were lysed. An aliquot of the lysates was used for immunoblotting as
shown in the top three rows. A second aliquot was used for immunocomplex
kinase assays using Aurora A antibody and histone H3 as substrate. Controls
established that Aurora A(D274N) was immunoprecipitated as efficiently as
wild-type Aurora A (data not shown). The bottom row shows an autoradiogram
documenting the incorporation of [32P]phosphate into histone H3 in this assay.
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significantly diminished (data not shown). Taken together, these
data show that stabilization of N-Myc is independent of Aurora A
kinase activity.
We therefore considered the possibility that Aurora A forms
a complex with either Fbxw7 or N-Myc in vivo to prevent degra-
dation of N-Myc. Consistent with this suggestion, immunopre-
cipitation experiments revealed that Aurora A was present in
Fbxw7a immunoprecipitates when both proteins were ex-
pressed in SH-EP cells and vice versa, suggesting that both
proteins can form a stable complex in vivo (Figure 6A). Since
Aurora A itself can be a substrate for Fbxw7-mediated ubiquiti-
nation and subsequent degradation, we considered the possi-
bility that elevated levels of Aurora A compete with N-Myc for
access to Fbxw7 (Fujii et al., 2006). We therefore tested whether
increasing amounts of Aurora A displace N-Myc from binding to
Fbxw7. However, expression even of high amounts of AURKA
did not displace N-Myc from a complex with Fbxw7a when all
three proteins were coexpressed by transient transfection in
SH-EP cells (Figure 6B). Furthermore, expression of AURKA
had no effect on Fbxw7-mediated degradation of cyclin E (Fig-
ure 6C) and c-Myc (data not shown), two additional substrates
of Fbxw7, further arguing that stabilization is not mediated by
competition among substrates of Fbxw7 (Koepp et al., 2001).
Alternatively, Aurora A might interact with N-Myc that is bound
to Fbxw7 and inhibit its degradation. To test this notion, we co-
transfected expression vectors encoding Aurora A and N-Myc
into SH-EP cells and immunoprecipitated lysates with either
control antibodies or antibodies directed against either protein
(Figure 6D). Immunoblots revealed that Aurora A was present
in N-Myc immunoprecipitates and vice versa (Figure 6D).
Furthermore, immunoprecipitations from lysates of IMR-32 cells
revealed the presence of endogenous Aurora A in N-Myc immu-
noprecipitates, demonstrating that the endogenous proteins
interact with each other; addition of nocodazole to arrest cells
in mitosis did not enhance the interaction, arguing that the inter-
action is not restricted to mitotic cells (Figure 6E). Aurora A and
N-Myc interacted both in the presence (Figure 6E) and in the
absence (Figure 6F) of a proteasome inhibitor, demonstrating
that the interaction is not due to the accumulation of partially
unfolded proteins when the function of the proteasome is in-
hibited.
Endogenous N-Myc was present in Fbxw7 immunoprecipitates
from IMR-32 cells (Figure S6C). Importantly, N-Myc mutated at
T58 and S62 (MYCN-mut) showed a reduction in its interaction
with Aurora A that mirrored the reduced interaction with Fbxw7
(Figure 6G). We concluded that Aurora A interacts preferentially
or exclusively with N-Myc that is bound to SCFFbxw7.
Degradation of Myc proteins occurs in a stepwise process,
and distinct sequence elements are required for ubiquitination
of Myc and for degradation of ubiquitinated Myc proteins (Herbst
et al., 2004). We therefore tested whether Aurora A interferes
with Fbxw7-mediated ubiquitination of N-Myc or with the subse-
quent degradation of ubiquitinated N-Myc. Transfection of
SH-EP cells with expression vectors encoding N-Myc and His-
tagged ubiquitin showed that N-Myc was strongly ubiquitinated.
Expression of Aurora A led to an accumulation of ubiquitinated
N-Myc that paralleled or exceeded the increase in N-Myc levels,
demonstrating that Aurora A acts at a postubiquitination step tostabilize N-Myc (Figure 6H). As expected, the ubiquitination of
N-Myc mutated at T58 and S62 was significantly reduced rela-
tive to wild-type N-Myc, and Aurora A had little effect on ubiqui-
tination of MYCN-mut (Figure S7A). Indeed, direct measure-
ments of the stability of ubiquitinated forms of N-Myc using
cycloheximide showed that expression of Aurora A inhibited
the turnover of ubiquitinated N-Myc (Figure S7B). Importantly,
Aurora A induced the accumulation of ubiquitinated N-Myc in
the presence of wild-type ubiquitin and in the presence of ubiq-
uitin in which K48 was replaced by arginine (K48R; Figure S7C).
In contrast, total levels of ubiquitination of N-Myc were strongly
reduced in the presence of a mutant ubiquitin in which all lysines
except K48 were mutated to arginine (K48-only), and Aurora A
failed to stabilize N-Myc under these conditions (Figure 6I, left
panel); this effect was specific for N-Myc since K48-only ubiquitin
supported ubiquitination of cyclin E as efficiently as wild-type
ubiquitin (Figure 6I, right panel). We concluded that Aurora A
stabilizes N-Myc by promoting the accumulation of ubiquitin
chains with linkages other than K48 that are degraded less effi-
ciently by the proteasome (Kim et al., 2007). Furthermore, muta-
tion of K63 of wild-type ubiquitin to arginine did not abolish the
ability of Aurora A to stabilize N-Myc, arguing that linkage via
K63 is not strictly required for stabilization by Aurora A (Fig-
ure S7C). Consistent with this suggestion, restoration of either
K63 or K11 into K48-only ubiquitin (generating K48/63 and K48/
11 ubiquitin) partially restored the ability of Aurora A to induce
the accumulation of ubiquitinated N-Myc, arguing that chains
linked via either residue can mediate stabilization of N-Myc
(Figure S7D).
In neuronal progenitor cells, S62 in N-Myc is phosphorylated
by cyclin B/Cdk1 complexes, suggesting that Aurora A might
stabilize N-Myc in the G2/M phase of the cell cycle (Sjostrom
et al., 2005). Consistently, levels of both Aurora A and N-Myc
increased when synchronized IMR-32 cells entered G2
(Figure S8A); also, Aurora A and N-Myc colocalized in mitotic
cells (Figure S8B). Furthermore, accumulation of cells in mitosis
using the spindle poison nocodazole led to a time-dependent
accumulation of N-Myc phosphorylated at S62 in IMR-32 cells,
both in the absence and in the presence of the proteasome inhib-
itor MG-132 (Figure 7A). As shown before, transient expression
of Aurora A led to an accumulation of N-Myc in SH-EP cells
(Figure 7B). N-Myc that accumulated under these conditions
was phosphorylated at both T58 and S62. In order to promote
phosphorylation of endogenous N-Myc at T58 and S62, we
used nocodazole and LY294002, an inhibitor of PI3-kinase.
Since Gsk3 is phosphorylated and inhibited by Akt, which is
downstream of PI3-kinase, addition of LY294002 activates
Gsk3 (Cross et al., 1995). In contrast to what has been observed
in neuronal progenitor cells, addition of nocodazole and
LY294002 had an only weakly additive effect on steady-state
levels of N-Myc in twoMYCN-amplified neuroblastoma cell lines
(Figure 7C). By itself, depletion of Aurora A reduced levels of N-
Myc protein 2-fold, as observed before. Depletion of Aurora A
synergized with the inhibitors in reducing steady-state levels of
N-Myc, and the combination of all three treatments all but elim-
inated N-Myc in both cell lines. Together, these data demon-
strate directly that high levels of Aurora A in MYCN-amplified
neuroblastoma cells interfere with the PI3-kinase-dependent
and mitosis-specific degradation of N-Myc.Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc. 73
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Figure 6. In Vivo Interactions of Aurora A with Fbxw7 and N-Myc
(A) Aurora A interacts with Fbxw7 in transfected cells. SH-EP cells were transfected with either control vectors or CMV-driven expression vectors encoding
Aurora A and FLAG-tagged Fbxw7a as indicated. Lysates were prepared 48 hr after transfection and precipitated with Aurora A, FLAG, or control antibodies.
Immunoblots of the input material (5% of the material used for precipitation) and of the immunoprecipitates are shown. MG-132 was added to the cells 6 hr before
harvesting.
(B) Aurora A does not displace N-Myc from Fbxw7. SH-EP cells were transfected and harvested as before. Lysates were immunoprecipitated with N-Myc or
control antibodies as indicated. MG-132 was added to the cells 12 hr before harvesting.
(C) Aurora A does not stabilize cyclin E. Immunoblots of SH-EP cells transfected with expression vectors encoding Aurora A, Fbxw7a, and either wild-type cyclin
E or cyclin E(T380A), a mutant that is not recognized by Fbxw7 (Clurman et al., 1996), are shown. Lysates were prepared 48 hr after transfection.
(D) Aurora A interacts with N-Myc in transfected cells. The experiment was performed as before. Lysates were immunoprecipitated with Aurora A, N-Myc, or
control antibodies as indicated. MG-132 was added to the cells 6 hr before harvesting.
(E) Interaction of endogenous N-Myc and Aurora A. IMR-32 cells were lysed and lysates were immunoprecipitated with antibodies directed against N-Myc or
control antibodies. Immunoprecipitates were probed with antibodies directed against Aurora A, N-Myc, or antibodies that recognize N-Myc phosphorylated
at T58 (N-Myc-pT58). Where indicated, nocodazole was added 18 hr before harvesting. MG-132 was added for 4 hr. The input lanes correspond to 2% of
the material used for immunoprecipitations.
(F) Endogenous N-Myc and Aurora A interact in the absence of MG-132. The experiment was performed from lysates of IMR-5 cells as described in the legend to
(E), except that neither MG-132 nor nocodazole was added to the cells. The asterisk denotes the heavy chain.
(G) Aurora A interacts with wild-type N-Myc, but not with N-Myc(T58A;S62A). SH-EP cells were transfected with the indicated expression vectors and analyzed as
in (A). Input lanes show 2.5% of the material used for immunoprecipitation.
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We report here that Aurora A has a critical function in stabilizing
N-Myc in neuroblastomas that carry an amplifiedMYCN gene. In
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Figure 7. Aurora A Stabilizes Endogenous N-Myc duringMitosis and
in the Absence of PI3-Kinase Activity
(A) Phosphorylation of S62 of N-Myc occurs in mitosis of MYCN-amplified
neuroblastoma cells. IMR-32 cells were incubated with nocodazole and/or
MG-132 as shown. At the indicated time points, cells were harvested
and probed with antibodies against Aurora A, N-Myc, N-Myc-pT58, and
N-Myc-pS62.
(B) Aurora A stabilizes N-Myc that is phosphorylated at T58 and S62. SH-EP
cells were transfected with expression vectors encoding Aurora A and
N-Myc as before and harvested after 48 hr. Lysates were probed with the indi-
cated antibodies.
(C) Endogenous Aurora A stabilizes N-Myc in the absence of PI3-kinase and
during mitosis in MYCN-amplified neuroblastoma cells. IMR-32 cells (upper
panels) or IMR-5 cells (lower panels) were infected with retroviruses express-
ing either control shRNA or two different shRNA vectors targeting AURKA.
Where indicated, pools of resistant cells were incubated with nocodazole,
LY294002, or both for 18 hr. Lysates were prepared and probed with
antibodies detecting total N-Myc, N-Myc phosphorylated at T58, or N-Myc
phosphorylated at S62 as shown.neuronal progenitor cells of the central nervous system, degra-
dation of N-Myc is linked to progression through mitosis since
it is initiated by phosphorylation at S62 by cyclin B/Cdk1 in
prophase (Sjostrom et al., 2005). Phosphorylation at S62 serves
as a priming site for Gsk3, which subsequently phosphorylates
T58 to initiate Fbxw7-mediated degradation (Sjostrom et al.,
2005). Gsk3 in turn is inhibited via phosphorylation by Akt. As
a result, signaling via PI3-kinase and Akt stabilizes N-Myc and
protects it from proteasomal degradation (Sjostrom et al.,
2005). Since N-Myc is required for the proliferation of neuronal
progenitors, the mitotic degradation of N-Myc that occurs in
the absence of growth factor-dependent signals allows cell-
cycle exit and commencement of differentiation (Knoepfler
et al., 2002; Sjostrom et al., 2005). Consistent with this view,
enforced expression of N-Myc, in particular of mutant alleles of
N-Myc that cannot be phosphorylated by Gsk3, induces prolifer-
ation and suppresses differentiation of neuronal progenitor cells
(Kenney et al., 2004).
In contrast to neuronal precursor cells, pharmacological inhi-
bition of PI3-kinase coupled with cell-cycle arrest in mitosis
had only moderate effects on N-Myc protein levels in MYCN-
amplified neuroblastoma cells. We showed that this is due to
elevated levels of Aurora A, which inhibit the mitotic degradation
of N-Myc in such cells. Conversely, coexpression of Aurora A
with N-Myc induces the accumulation of N-Myc that is phos-
phorylated at both S62 and T58. As a result, high levels of Aurora
A effectively uncouple degradation of N-Myc from PI3-kinase-
dependent signaling in neuroblastoma. We propose that
elevated levels of Aurora A may inhibit the cell-cycle exit of neu-
roblasts during late embryonic and early postnatal development
and thereby contribute to the genesis of neuroblastoma.
Notably, the relationship of Aurora A and N-Myc in neuroblas-
toma has properties of a positive feedback loop: expression of
AURKA is elevated in MYCN-amplified neuroblastoma and
induced by activation of N-Myc in culture (Berwanger et al.,
2002), and conversely, Aurora A stabilizes the N-Myc protein.
Amplification of either gene might therefore lock this loop in an
active state. Attempts to test this model by enforcing stable
expression of Aurora A failed since retroviral expression of
either wild-type or kinase-dead Aurora A suppressed colony
formation in multiple cell lines, arguing that additional genetic
events must occur that allow tumor cells to accommodate
elevated levels of AURKA. A model summarizing our findings is
shown in Figure 8.
Previous work has demonstrated that specific sequences in
Myc proteins that are highly conserved in evolution (Mycboxes)
are required for ubiquitination of Myc (Mycbox I, surrounding
T58 and S62) and the subsequent degradation of ubiquitinated
Myc (Mycbox III), arguing that both steps involve distinct mech-
anisms (Herbst et al., 2004). Aurora A inhibits the degradation of
ubiquitinated N-Myc, similar to what is observed for deletion
mutants lacking Mycbox III. Our finding that Aurora A also(H) Aurora A induces the accumulation of ubiquitinated N-Myc. SH-EP cells were transfected with the indicated expression vectors. Cells were harvested 48 hr
after transfection. Four hours before harvesting, MG-132 (25 mM) was added to block proteasomal degradation. Ubiquitinated proteins were recovered on Ni-NTA
agarose and detected with N-Myc antibodies.
(I) Aurora A does not promote the accumulation of N-Myc carrying K48-linked polyubiquitin chains. Left panel: N-Myc ubiquitination assays were performed as
above using either wild-type ubiquitin or ubiquitin in which all lysine residues except K48 were mutated to arginine (K48-only). Right panel: ubiquitination of cyclin
E was used as a control to demonstrate that K48-only ubiquitin is not generally deficient in conjugation.Cancer Cell 15, 67–78, January 6, 2009 ª2009 Elsevier Inc. 75
Cancer Cell
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zole argues against a simple sequestration of N-Myc from the
proteasome at the spindle. Two possible mechanisms can
account for our observations. First, binding of Aurora A to
N-Myc might inhibit ubiquitination at individual lysine residues
in N-Myc that are critical for degradation, and this effect may
be missed by looking at total ubiquitination of N-Myc. An alterna-
tive explanation is supported by our observation that Aurora A
requires the presence of K63 or K11 to promote the accumula-
tion of ubiquitinated N-Myc. This suggests that Aurora A
promotes the synthesis of non-K48-linked ubiquitin chains that
do not support degradation (Kim et al., 2007). The specificity of
chain linkage is dictated by a combination of ubiquitin ligase
and the ubiquitin-conjugating enzyme (Ubc) that is used for ubiq-
uitination (Kim et al., 2007): for example, Fbxw7 uses Cdc34 to
synthesize K48-linked polyubiquitin chains to degrade Myc
(N.P., unpublished data). Therefore, we propose that Aurora A
recruits Ubcs that can conjugate to K11, K63, or both in addition
to K48; one candidate is Ube2n, which directs the synthesis of
K63-linked polyubiquitin chains and interacts with Aurora A
(Ewart-Toland et al., 2003). At present, we have been unable to
detect complexes of N-Myc, Aurora A, and Ube2n, so the
precise role of Ube2n or other Ubcs in the stabilizing function
of Aurora A remains to be determined. If factors that act in
a manner similar to Aurora A also exist for c-Myc, this model
may explain the recent observation that HectH9, a ubiquitin
ligase that assembles the synthesis of predominantly K63-linked
chains on c-Myc, assembles predominantly K48-linked chains
on N-Myc (Adhikary et al., 2005; Zhao et al., 2008). Furthermore,
ubiquitination of Myc by HectH9 or Skp2 stimulates the
transcriptional activity of Myc in addition to regulating turnover;
similarly, it is possible that Aurora A—via stabilizing ubiquitinated
N-Myc—activates its function as a transcription factor (Adhikary
et al., 2005; Kim et al., 2003).
AURKA is highly expressed relative to normal tissue and
amplified in multiple human tumors (Zhou et al., 1998). Ectopic
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The mitotic degradation of N-Myc has been
proposed to couple growth factor-dependent
signals to N-Myc levels at the start of the cell cycle
and thereby allow cell-cycle exit of neuroblasts
during the development of the nervous system
(Sjostrom et al., 2005). We propose that high levels
of Aurora A in MYCN-amplified neuroblastoma
(either due to an amplification of the AURKA
gene or due to activation of AURKA mRNA
expression in response to the high N-Myc levels)
uncouple this regulatory circuit and maintain
neuroblastoma cells in a proliferative state inde-
pendently of the presence of external growth
factors.
expression of AURKA transforms rodent
fibroblasts in culture and induces hyper-
plasia and mammary tumors when ex-
pressed under the control of an MMTV
promoter in transgenic mice (Bischoff
et al., 1998; Wang et al., 2006). Together,
these observations provide strong evidence for an oncogenic
function of Aurora A in several human tumors.
Amplification of the AURKA gene has been taken as evidence
that the kinase activity of Aurora A is under selective pressure
during tumorigenesis, and, as a consequence, inhibitors of
Aurora A kinase are being developed as anticancer therapeutics
(Carvajal et al., 2006). In support of this approach, transformation
of rodent fibroblasts by Aurora A depends on its kinase activity
(Bischoff et al., 1998). Furthermore, the ability of Aurora A to
enhance translation of c-Myc and prevent cellular senescence,
which may be critical for its ability to transform rodent fibro-
blasts, depends on phosphorylation of cytoplasmic polyadeny-
lation element binding protein (CPEB) (Groisman et al., 2006).
In contrast, Aurora A kinase activity is not required for stabiliza-
tion of N-Myc or for the ability of Aurora A to induce centrosome
duplication, suggesting that inhibition of Aurora A kinase may fail
to inhibit critical oncogenic functions of Aurora A (Meraldi et al.,
2002). Aurora A had no effect on the stability of cyclin E or
c-Myc, other proteins that are degraded by Fbxw7, suggesting
that the function of Aurora A described here contributes selec-
tively to the development of N-Myc-dependent tumors. In addi-
tion to neuroblastoma, both N-Myc and Aurora A are also
involved in the genesis of medulloblastoma (Neben et al., 2004).
Similarly, both MYCN and AURKA are expressed at high levels
in glioblastoma, astrocytoma, and prostate carcinoma, suggest-
ing that stabilization of N-Myc by Aurora A may not be restricted
to childhood tumors. Finally, both Aurora A and N-Myc have been
implicated in the genesis of acute myelocytic leukemia (AML),
arguing that stabilization of N-Myc may contribute to Aurora A-
dependent tumorigenesis in several entities.
Notably, elevation of N-Myc levels may also contribute to
tumor-relevant phenotypes, such as the ability to induce
genomic instability and aneuploidy, that have been ascribed to
the mitotic functions of Aurora A. For example, the mitotic check-
point geneMAD2L1 is a direct target of N-Myc (Berwanger et al.,
2002), and enhanced expression of MAD2L1 is oncogenic and
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pression (Sotillo et al., 2007). Taken together, our data suggest
that deregulation of N-Myc may contribute significantly to the
oncogenic properties of Aurora A.
EXPERIMENTAL PROCEDURES
Cell Culture and Patient Samples
Neuroblastoma cell lines stably expressing the murine ecotropic receptor with
a hygromycin or neomycin resistance gene were grown in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum and hygromycin
(100 mg/ml) or G418 (200 mg/ml), respectively. Treatment with 4-hydroxyta-
moxifen (4-OHT; 200 nM), cycloheximide (50 mg/ml), MG-132 (5–25 mM),
nocodazole (0.1 mg/ml), LY294002 (50 mM), and hesperadin (100 nM) was
carried out as indicated. For colony assays, cells were fixed with 70% ethanol
and stained with crystal violet. FACS analysis was performed using propidium
iodide staining of ethanol-fixed cells, a FACSCalibur flow cytometer (BD
Biosciences), and ModFit LT software.
Primary neuroblastoma samples were obtained from patients participating
in the German Neuroblastoma Study, and informed consent was obtained
within the German Neuroblastoma Study Group.
Plasmids, Transfection, and Retroviral Infection
shRNA-expressing vectors were based on the pSUPER.retro.puro plasmid
and were either picked from a preexisting shRNA library (Berns et al., 2004)
or cloned from oligonucleotides. MYCN and AURKA coding sequences were
cloned into the BamHI or the BamHI and XhoI sites of pcDNA3, respectively.
Expression vectors encoding the Fbxw7a and Fbxw7g isoforms (p3xFLAG-
FBXW7-MYC-CMV) and those encoding cyclin E1 wild-type and T380A
mutant were obtained from B.E. Clurman (University of Washington, Seattle).
Site-directed mutagenesis using the QuikChange XL Site-Directed Mutagen-
esis Kit (Stratagene) was performed to generate constructs expressing mutant
MYCN or AURKA.
Cells were transiently transfected using the calcium phosphate method with
varying amounts of DNA (2–30 mg). For retroviral transduction, the Phoenix-
Eco helper cell line (American Type Culture Collection) was used. Control
FACS analyses showed that less than 5% of cells underwent apoptosis under
any experimental condition.
Microarray Experiments and qRT-PCR
Fluorescently labeled cDNA was prepared from 2 mg preamplified total RNA by
oligo(dT)-primed synthesis using CyScript reverse transcriptase in the pres-
ence of aminoallyl-dUTP followed by incubation with either Cy3 or Cy5 NHS
esters (Amersham CyScribe Post-Labeling Kit). Each experiment was per-
formed as a sandwich hybridization using two arrays, and two independent
arrays were performed in a flip-color design for each data point. Data from
all four hybridizations were averaged for further statistical analysis.
For qRT-PCR, total RNA was transcribed into cDNA using random hexanu-
cleotide primers and M-MLV reverse transcriptase. qRT-PCR was performed
in triplicates with cDNA corresponding to 40 ng total RNA using ABsolute
QPCR SYBR Green Mix (ABgene) on an Mx3000P system (Stratagene) at
60C annealing temperature. Relative expression was calculated according
to the DDCt relative quantification method using RPS14 as a calibrator, except
where stated otherwise. Error bars represent standard deviation of triplicates.
Immunoblot and Immunoprecipitation
Whole-cell extracts were prepared using three rounds of freeze/thaw in buffer
containing 50 mM Tris (pH 8), 150 mM NaCl, 1% NP-40, and a cocktail of
phosphatase and protease inhibitors. Antibodies used are listed in the Supple-
mental Experimental Procedures.
For immunoprecipitation, lysis was carried out on ice in buffer containing
50 mM Tris (pH 7.5), 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, and inhibitors
(as above) followed by sonication. Coimmunoprecipitation was performed
using 1 mg of antibodies and 150–300 mg lysate for exogenous proteins or
2–9 mg for endogenous proteins.Kinase and Ubiquitination Assays
For immunocomplex in vitro kinase assay, 800 mg lysate was immunoprecipi-
tated with Aurora A or control antibody, washed and equilibrated in kinase
buffer (50 mM Tris [pH 7.4], 10 mM MgCl2, 1 mM DTT, and phosphatase
and protease inhibitors), incubated for 30 min at 30C with 5 mCi [g-32P]ATP
and 1.5 mg recombinant histone H3, separated on a 15% SDS polyacrylamide
gel, dried, and subjected to autoradiography. Ubiquitination assays were
performed as described in Adhikary et al. (2005).
ACCESSION NUMBERS
Microarray results described herein are accessible at ArrayExpress (http://
www.ebi.ac.uk/microarray-as/ae/) under the accession number E-MEXP-
1496.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and eight figures and can be found with this article online at http://
www.cancercell.org/supplemental/S1535-6108(08)00408-X.
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